Sol-Gel Technologies (SLGL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sol-Gel Technologies has struck six exclusive licensing deals to market their dermatology products TWYNEO and EPSOLAY in most European countries and South Africa, with financials involving upfront and milestone payments up to low 7-digit USD figures, alongside future sales royalties. These agreements, which include commitments to minimum annual sales, build on Sol-Gel’s existing partnerships in the US, Canada, and China, showcasing the growing global confidence in their products. The company continues to advance its clinical trials for other potential treatments, further strengthening its competitive position in the dermatology pharmaceutical market.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.
